EVRY, FRANCE, Biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, announced the closing of a $4.9 million.
InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, announced today the closing of a $4.9 million (EURO3.7 million) Series B round of funding.
This round has been led by Pradeyrol Developpement and private equity funds Fa Diese and FRCI (Fonds Regional de Co-Investissement d'Ile-de-France). Historical InnaVirVax's investors CapDecisif 2 and G1J Ile-de-France also participated in the round.
This funding allows the company to pursue its development, and especially to conduct the phase I/IIa clinical trials of VAC-3S immunotherapy, which will be carried out in two clinical centers of the Assistance Publique - Hopitaux de Paris, namely the PitiƩ Salpetriere and Cochin Hospitals. Moreover, InnaVirVax will also be able to develop other research projects relying on the same scientific background such as the comprehension of immune dysregulations during severe pathologies.
Localized at the Genopole of Evry, a Paris Biopark, InnaVirVax is a biopharmaceutical company specializing in research and development of therapeutic and diagnostic solutions for severe diseases related to immune dysregulations. Based on the understanding of such immune dysregulations, the Company has developed a portfolio of innovative programs in the areas of oncology and HIV. Incorporated in 2008, the Company has since received support from the French Ministry of Higher Education and Research, OSEO (the French innovation agency), the French National Research Agency, the 'Centre Francilien de l'Innovation' and the regional seed funds CapDecisif and G1J Ile-de- France.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
